Innovative Targeting Strategies in Breast Cancer Therapy is a comprehensive reference addressing the challenge of non-specific drug distribution in the body, along with severe toxicity and adverse effects, by offering insights into targeted breast cancer treatment. It further educates researchers on formulating and developing novel carriers with target-specific attributes (such as targeted liposomes, nanoparticles, micelles, and dendrimers), contributing to a more refined approach to breast cancer. This book's content is presented in 12 chapters. The first chapters introduces the reader to the different breast cancer therapies followed by indepth information on targeting . Recognizing the need for targeted drug delivery in breast cancer treatment, this book presents an encompassing compilation of advanced research and formulation strategies. By focusing on effectively targeting cancer cells, the book mitigates dose-related toxicity associated with cytotoxic drugs, providing a comprehensive resource for improved treatment approaches. Research in oncology, pharmacology, medical researchers, biomedical engineers and clinical professionals will find this an essential reference.

� propos des auteurs

Dr. Pankaj Kumar Singh, Ph.D., is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research-Hyderabad (NIPER-Hyderabad), India. He earned his Doctorate in Pharmaceutics from CSIR-Central Drug Research Institute, Lucknow. Dr. Singh is actively involved in various scientific and socially impactful projects funded by prestigious organizations, including TSCOST-DBT, CCRUM, DST, ICMR, and the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India.

Dr. Manish K. Chourasia, is currently working as a Senior Principal Scientist in the Division of Pharmaceutics and Pharmacokinetics at CSIR-Central Drug Research Institute (CDRI), Lucknow, a premium drug research institute in India. He received his PhD in Pharmaceutical Sciences from Dr. Harisingh Gour University, Madhya Pradesh, India and carried out his post-doctoral studies at Department of Pharmacy, National University of Singapore, Singapore. Having acquired valuable experience in both industry and academia, he subsequently joined the role of a scientist at CSIR-CDRI almost two decades ago. He has played a significant role in advancing the field of nanoparticle-based drug delivery for breast cancer, aiming to enhance the therapeutic outcome. He has published 80+ scientific papers including high-impact journal reviews. He has supervised more than 50 MS students and PhD students.

Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the University of Technology Sydney (UTS). Dr Dua has been recognised and named as one of Australia's Top 250 researchers in 2025 and 2024 in Research Magazine by "The Australian" in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua's research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua's research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

Dr. Sachin Kumar Singh, is working as professor and head of Pharmaceutical Chemistry and Quality Assurance at School of Pharmaceutical Sciences, Lovely Professional University, India. He is an honorary professor at Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), School of Public Health, University of Technology Sydney, Australia and School of Medical and Life Sciences, Sunway University, 47500 Sunway City, Malaysia. He has 14 years of teaching and research experience. Dr. Singh has completed one DST-SERB funded project on development of SNEDDS of Polypeptide-k for treatment of diabetes mellitus. He has published 500 plus research papers with cumulative impact of 1500 plus, authored 5 books and 25 book chapters. He has 10 granted patents to his credit. He is expert in development of novel drug delivery systems, synbiotics based formulations, analytical and bioanalytical method development and BA-BE studies. He has graduated 17 PhD students and 35 M Pharmacy students and currently graduating 3 masters and 6 PhD students. He is also featured under top 2% scientists of world as per the list of 2021, 2022 and 2023, published by Stanford University, USA. Currently his "h" index is 48 with 11000 plus citations. He is a recipient various national awards including Dr. B.C. Deb memorial award for popularization of science-2020 (honoured by Indian Science Congress Association), Bharat Shiksha Ratan Award-2014 (by Global Society for Health and Educational Growth, Delhi, India) and Bharat Gaurav Puraskar-2022 (by KTK outstanding achievers and education foundation, New Delhi) and Distinguished Alumnus Award (by Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka).

Dr. Kumar Guru is currently at NIPER in Hyderabad. He holds a PhD in pharmaceutical science.His research group mainly focus on basic and applied drug discovery in cancer biology and on role of drug tolerant persistent cell and chemotherapy induced tumor dormancy in cancer. He explores the survival mechanism of these dormant tumors through Autophagy, epigenetic, RNA methylation, efferocytosis, ferroptosis, EMT and YAP/TAZ mechanism.

Les informations fournies dans la section � A propos du livre � peuvent faire r�f�rence � une autre �dition de ce titre.

Description de la librairie

Visitez la page d�accueil du vendeur

Informations commerciales relatives au vendeur

Edward Bowditch Ltd
Exstowe, Exton, Exeter, EX3 0PP, United Kingdom

Conditions de vente et de livraison

Conditions g�n�rales de vente

Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch

Droit de r�tractation

Si vous �tes un consommateur, vous pouvez vous r�tracter du pr�sent contrat dans les conditions indiqu�es ci-dessous. Etre un consommateur signifie �tre une personne physique qui agit � des fins qui n'entrent pas dans le cadre de son activit� commerciale, industrielle, artisanale ou lib�rale.

Informations standardis�es sur la r�tractation

Droit de r�tractation:

Vous avez le droit de vous r�tracter du pr�sent contrat sans donner de motif dans un d�lai de quatorze jours.

Le d�lai de r�tractation expire quatorze jours apr�s le jour o� vous-m�me, ou un tiers autre que le transporteur et d�sign� par vous, prend physiquement possession du dernier bien, lot ou pi�ce.

Pour exercer le droit de r�tractation, vous devez nous Revaluation Books, Exstowe, Exton, EX3 0PP, Exeter, United Kingdom, 44 1179083586, notifier votre d�cision de r�tractation du pr�sent contrat au moyen d'une d�claration d�nu�e d'ambigu�t� (par exemple, lettre envoy�e par la poste, t�l�copie ou courrier �lectronique). Vous pouvez utiliser le mod�le de formulaire de r�tractation mais ce n'est pas obligatoire. Vous pouvez �galement remplir et transmettre une d�claration claire � cette fin sur notre site internet � �Vos commandes� dans �Votre compte�. Si vous utilisez cette option, nous vous enverrons sans d�lai un accus� de r�ception de la r�tractation sur un support durable (par exemple, par courriel).

Pour que le d�lai de r�tractation soit respect�, il suffit que vous transmettiez votre communication relative � l'exercice du droit de r�tractation avant l'expiration du d�lai de r�tractation.

Effets de la r�tractation :

En cas de r�tractation de votre part du pr�sent contrat, nous vous rembourserons tous les paiements re�us de vous, y compris les frais de livraison (� l'exception des frais suppl�mentaires d�coulant du fait que vous avez choisi, le cas �ch�ant, un mode de livraison autre que le mode moins co�teux de livraison standard propos� par nous) sans retard excessif et, en tout �tat de cause, au plus tard quatorze jours � compter du jour o� nous sommes inform�s de votre d�cision de r�tractation du pr�sent contrat. Nous proc�derons au remboursement en utilisant le m�me moyen de paiement que celui que vous aurez utilis� pour la transaction initiale, sauf si vous convenez express�ment d'un moyen diff�rent; en tout �tat de cause, ce remboursement n'occasionnera pas de frais pour vous.

Nous pouvons diff�rer le remboursement jusqu'� ce que nous ayons re�u le bien ou jusqu'� ce que vous ayez fourni une preuve d'exp�dition du bien, la date retenue �tant celle du premier de ces faits.

Vous devrez renvoyer ou rendre le bien, � Revaluation Books, Edward Bowditch Ltd, Clifton Heights, Triangle West, BS8 1EJ, Bristol, United Kingdom, 44 1179083586, sans retard excessif et, en tout �tat de cause, au plus tard quatorze jours apr�s que vous nous aurez communiqu� votre d�cision de r�tractation du pr�sent contrat. Ce d�lai est r�put� respect� si vous renvoyez le bien avant l'expiration du d�lai de quatorze jours. Vous devrez prendre en charge les frais directs de renvoi du bien. Votre responsabilit� n'est engag�e qu'� l'�gard de la d�pr�ciation du bien r�sultant de manipulations autres que celles n�cessaires pour �tablir la nature, les caract�ristiques et le bon fonctionnement de ce bien.

Exceptions au droit de r�tractation

Le droit de r�tractation ne s'applique pas � :

la fourniture d'un contenu num�rique (dont livres �lectroniques) non fourni sur un support mat�riel (tel qu'un CD ou un DVD), si vous avez accept� au moment de la passation de votre commande que nous commencions la fourniture de celui-ci et renonc� � votre droit de r�tractation ;
la fourniture d'un journal, d'un p�riodique ou d'un magazine, sauf pour les contrats d'abonnement � ces publications.

Formulaire de r�tractation

(A compl�ter et renvoyer seulement si vous souhaitez-vous r�tracter du pr�sent contrat)

A l'attention de : (Revaluation Books, Exstowe, Exton, EX3 0PP, Exeter, United Kingdom, 44 1179083586)

Je vous notifie par la pr�sente ma r�tractation du contrat portant sur la vente des produits suivants :

num�ro de commande :

Command� le/re�u le :

Mon nom et mon adresse :

Signature (seulement si ce formulaire est notifi� en version papier) :

Date

Conditions d'exp�dition

Orders usually dispatched within two working days.

Frais d?exp�dition de Royaume-Uni�vers�Etats-Unis

Frais d?exp�dition de Royaume-Uni�vers�Etats-Unis
Quantit� command�e	7 � 14 jours ouvr�s	2 � 3 jours ouvr�s
Premier article	EUR 14.47	EUR 28.95

Les d�lais de livraison sont fix�s par les vendeurs et varient en fonction du transporteur et du lieu. Les commandes transitant par les douanes peuvent �tre retard�es et les acheteurs sont responsables de tous les droits ou frais associ�s. Les vendeurs peuvent vous contacter au sujet de frais suppl�mentaires afin de couvrir toute augmentation des co�ts d'exp�dition de vos articles.